North America

SHERIDAN, WYOMING - December 4, 2025 - Cresta Fund Management is expanding its senior leadership team to support the next phase of growth, appointing industry veteran David Altshuler as Partner and Head of Capital Formation and promoting two long-standing team members into expanded roles. The Dallas-based private equity firm, which focuses on energy infrastructure across industrial, logistics and agricultural sectors, is sharpening its institutional capital-raising capabilities as limited partners seek specialist managers with operational depth and clear energy-transition strategies.

Bringing a Capital Formation Heavyweight Into the Partnership

SHERIDAN, WYOMING - December 4, 2025 - Workday has secured its position as a four-time Leader in the 2025 Gartner® Magic Quadrant™ for Financial Planning Software, underscoring how the company's AI-enabled platform is becoming a strategic hub for finance teams navigating volatility, pricing pressure and tighter capital markets. The recognition highlights Workday Adaptive Planning's role in helping financial planning and analysis (FP&A) organizations shift from static budgeting to always-on, scenario-based planning.

Four Years as a Gartner Leader in Financial Planning

SHERIDAN, WYOMING - December 4, 2025 - Ubicquia has unveiled a coordinated next-generation smart streetlighting portfolio built around its new UbiCell® Micro controller, major enhancements to the UbiVu® infrastructure management platform and the launch of UbiScout™, an AI video accessory that turns existing streetlights into multi-purpose urban sensors for safety, mobility and energy efficiency.

Integrated portfolio targets utilities and cities under pressure to modernize

With grid operators and municipalities facing rising energy costs, decarbonization targets and aging infrastructure, Ubicquia's new offering is designed to make large-scale modernization of streetlighting networks faster and more manageable. The company positions the portfolio as a way to deliver asset intelligence, remote control and AI analytics without wholesale replacement of installed luminaires.

SHERIDAN, WYOMING - December 4, 2025 - Velvære, a 60-acre wellness-focused, ski-in/ski-out residential community in Deer Valley's new East Village, has secured a restructured $555 million construction revolver to complete its luxury estates, vertical residences and private amenities, underscoring continued investor appetite for high-end U.S. residential destination projects.

$555 million revolver anchors a $1 billion alpine masterplan

The new capital structure combines $197 million in fresh financing from Anchor Loans with existing commitments into a multi-product construction revolver. Arranged and advised by LFB Ventures, with equity backing from Toba Capital, the facility is designed to fund land development, amenity construction and vertical build-out across the project's diverse product mix.

SHERIDAN, WYOMING - December 4, 2025 - Vortex Control Technologies (VCT) has signed a fleet-wide retrofit agreement with Norwegian to equip all Boeing 737-800 aircraft with its patented Finlet fuel-saving modification, aligning the Nordic carrier's cost discipline with a more aggressive sustainability strategy in short- and medium-haul aviation.

Aerodynamic retrofits move from trial to fleet standard

Under the new agreement, Norwegian will install VCT Finlets across its entire 737-800 fleet, following in the footsteps of early adopters such as Avelo Airlines, SunExpress and the U.S. Air Force. The deal marks a pivot from pilot programs to full-fleet deployment, signaling growing confidence among operators that incremental aerodynamic improvements can deliver material savings at scale.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

SHERIDAN, WYOMING - December 2, 2025 - Roche has secured FDA 510(k) clearance with a CLIA waiver and CE IVDR certification for its first point-of-care test to diagnose Bordetella infections, providing primary care and emergency clinicians with PCR-accurate results in just 15 minutes to help control whooping cough and related diseases.

Fast, PCR-accurate diagnosis at the point of care

Running on the cobas® liat system, Roche's new assay delivers lab-quality PCR results in GP offices and emergency rooms within a standard consultation. The 15-minute turnaround allows physicians to move from suspicion to definitive diagnosis immediately, supporting timely antibiotic prescribing that can prevent severe complications and reduce onward transmission.

SHERIDAN, WYOMING - December 2, 2025 - Roche is re-entering the frontline of Alzheimer's disease drug development, after new Phase I/II data showed its next-generation antibody trontinemab cleared amyloid plaques below the threshold of positivity in the vast majority of treated patients while keeping key safety signals under tight control.

Early Brainshuttle data show deep amyloid clearance

In the ongoing Brainshuttle AD Phase I/II study, 92% of patients treated with trontinemab achieved amyloid levels below 24 centiloids, the PET scan threshold commonly used to define amyloid positivity. The data, presented at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, mark one of the strongest plaque-clearing signals yet seen in a mid-stage program.